Jennifer Lachey - 14 Jun 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
14 Jun 2022
Net transactions value
+$2,820
Form type
4
Filing time
14 Jun 2022, 18:57:12 UTC
Previous filing
13 May 2022
Next filing
15 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $2,820 +9,400 +11% $0.3000* 95,100 14 Jun 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -9,400 -14% $0.000000 56,705 14 Jun 2022 Common Stock 9,400 $0.3000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.